{"product_id":"slu-pp-322-wholesale","title":"SLU-PP-322 5mg - Wholesale","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSLU-PP-322 (also referred to in published literature as SLU-PP-332) is a synthetic small molecule and pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ), nuclear receptors that regulate mitochondrial function, oxidative metabolism, and energy expenditure in metabolically active tissues including skeletal muscle, cardiac muscle, and adipose tissue. It is classified as an exercise mimetic compound and is currently investigational, with no FDA approval. Research has been conducted primarily at the University of Florida and Saint Louis University.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMechanism of Action\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eSLU-PP-322 activates ERRα (with approximately 4-fold selectivity over ERRγ), triggering an acute aerobic exercise-like gene expression program. This activation upregulates genes involved in mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and skeletal muscle fiber type remodeling toward oxidative (Type IIa) fibers. The compound does not affect appetite, food intake, or hormonal axes.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eResearch Applications and Preclinical Findings\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eIn diet-induced obese and ob\/ob mouse models, twice-daily administration for 28 days resulted in approximately 12% reduction in body weight and significantly attenuated fat mass accumulation. Normal-weight mice demonstrated up to 70% improvement in exercise endurance and 45% increase in running distance. Additional preclinical research suggests cardioprotective effects including improved cardiac ejection fraction, reduced fibrosis, and normalized fatty acid oxidation in heart failure models. Potential applications are being explored in metabolic syndrome, obesity, sarcopenia, muscular dystrophy, and age-related metabolic decline.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAdministration\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eCurrently administered via subcutaneous injection in research settings. Oral formulation development is ongoing. Not FDA-approved; human trials have not yet been reported.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePotential Adverse Effects\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eNo severe adverse effects reported in preclinical models to date. Potential mild effects include injection site irritation, fatigue, and headache. Long-term human safety data is absent.\u003c\/p\u003e","brand":"Aureon Bioscience","offers":[{"title":"Default Title","offer_id":46648007458974,"sku":null,"price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0747\/1543\/1070\/files\/SLU-PP-322_3x_995db9e9-9d1c-4891-9f85-8fe216b0e1c3.png?v=1774860344","url":"https:\/\/checkout.aureonbioscience.com\/products\/slu-pp-322-wholesale","provider":"Aureon Bioscience","version":"1.0","type":"link"}